August 27, 2026
Moderna is raising $2 billion through a zero-coupon convertible note offering, diluting existing shareholders.
What happened
Moderna announced a proposed $2 billion offering of zero-coupon convertible senior notes due 2032, with an additional $300 million purchase option for initial buyers. The stock fell 4.6 percent on the day, a move larger than 79 percent of its daily changes over the last three years.
Why it matters
A convertible note pays no cash interest, which reduces the burden on Moderna's cash flows, but it can turn into equity later. When those notes convert, the company must issue new shares, spreading its future earnings across a larger base and shrinking the value of each existing share. The stock dropped because the market immediately priced in that future dilution.
The case against
The zero-coupon structure tells investors the company is preserving its cash deliberately, which is sensible while it invests heavily in a pipeline that is not yet profitable. If the funds successfully bring new products to market, the growth could outweigh the dilution, making the sale of shares at this price look like a smart deal.
What settles it
The final terms of the deal, especially the conversion premium, will show how much upside current shareholders must give up to secure the $2 billion.